A multi-center, randomized, double-blind, placebo-controlled, multiple dose study to investigate safety and tolerability of RG1662 in individuals with Down Syndrome.

Trial Profile

A multi-center, randomized, double-blind, placebo-controlled, multiple dose study to investigate safety and tolerability of RG1662 in individuals with Down Syndrome.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2014

At a glance

  • Drugs Basmisanil (Primary)
  • Indications Behavioural symptoms; Cognition disorders; Down syndrome
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jul 2013 Planned End Date changed from 1 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 23 May 2013 Planned end date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top